

Acknowledgements

FINANCIAL SUPPORT

Pfizer Inc., New York, NY, USA, provided support for meetings of the Latin American Working Group on Gram Positive Resistance. Pfizer Inc. had no involvement in the collection, analysis and interpretation of data, in the writing of the manuscripts, or in the decision to submit the articles for publication.

MANUSCRIPT PREPARATION

The support provided by Choice Pharma (Hitchin, UK), funded by Pfizer Inc., consisted of manuscript formatting and writing assistance.

DISCLOSURES

E. Rodríguez-Noriega: Advisory Board member for Pfizer; consultant for Pfizer, Wyeth, Johnson & Johnson and Novartis; received research grants from Pfizer, Wyeth, Johnson & Johnson, Schering-Plough and Cerexa.

C. Seas: Advisory Board member and consultant for Pfizer; received research funding from Therevance, Cerexa, Schering-Plough and Avexa.

M. Guzmán-Blanco: Advisory Board member for Pfizer, Merck and BD; consultant for Pfizer, Wyeth and Janssen; received research funding from Wyeth and Merck.

C. Mejía: Advisory Board member for Pfizer and Abbott; consultant for Pfizer; received funding from Tibotec for HIV research, from Avexa for studies in HIV treatment and from Merck for participation in the SMART study.

C. Alvarez: Advisory Board member for Pfizer; consultant for Pfizer, Janssen-Cilag, GlaxoSmith-Kline, Baxter, Merck Sharp & Dhome and Bristol Myers Squibb.

L. Bavestrello: Advisory Board member and consultant for Pfizer.

J. Zurita: Advisory Board member and consultant for Pfizer; received research grant from Wyeth.

J. Labarca: Advisory Board member for Pfizer; consultant for Pfizer, Merck Sharp & Dhome and Wyeth; investigator for linezolid studies funded by Pfizer

C.M. Luna: Advisory Board member for Pfizer, Bayer and Wyeth; consultant for Pfizer; speaker for AstraZeneca.

M.J.C. Salles: Advisory Board member for Pfizer and Wyeth; consultant or speaker for Pfizer, Wyeth, Merck and United Medicals.

E. Gotuzzo: Advisory Board member and consultant for Pfizer; received research grants from Merck, Sharp & Dohme; TIBOTEC consultant for Sanofi Pasteur.